Register for our free email digests:
Latest From Sanwa Kagaku Kenkyusho Co. Ltd.
Although it approved fewer new products last fiscal year, Japan granted access to a number of important new therapies, including in oncology and several for the first time worldwide, helped by continuing reforms at its regulatory body.
MP Advisors sees a cumulative biosimilars opportunity of around JPY400 billion ($3.31 billion) in Japan over the next five years as some big-selling biologics come off local patent. But the next few years will provide further clarity on the value of different strategies for complex monoclonal antibody (mAb) biosimilar penetration in the country.
BMS’ Orencia, Sanofi’s Lyxumia, Chugai’s Perjeta and others are now cleared for the market after receiving National Health Insurance price listings.
R&D in the international pharmaceutical industry appears in ruder health than some might think. In 2012, the number of new active substances (NAS) launched in their first markets worldwide hit 39 – the highest tally since 2000, new research from Scrip Intelligence has found.
- Therapeutic Areas
- Neurology, Nervous System
- vasopharm Biotech GMBH
- Western Europe
- Parent & Subsidiaries
- vasopharm GMBH
- Senior Management
Christian Wandersee, CEO
Frank Tegtmeier, PhD, CSO
- Contact Info
Phone: (49) 931 35 90 99-0
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.